{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:15:45Z","timestamp":1790043345119,"version":"4.0.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Oxaliplatin-induced hypersensitivity reactions (HSRs) are commonly encountered in first-line therapies for various malignancies. Recent research indicates that these reactions can include cytokine release reactions (CRRs), which are characterized by a marked increase in interleukin-6 (IL-6) levels, sometimes rising as much as 40-fold. Standard management strategies for HSRs typically involve desensitization protocols and routine treatments. However, these conventional approaches may be insufficient for managing CRRs. Preliminary studies suggest that tocilizumab, an IL-6 receptor (IL-6R) antagonist, may play a crucial role in mitigating CRRs. In our case, a 65-year-old male with stage IV extranodal NK\/T-cell lymphoma developed a severe HSR on day 1 following the infusion of oxaliplatin during his fourth chemotherapy cycle. This reaction was marked by a substantial increase in IL-6 levels. Despite the administration of standard treatments, including epinephrine and corticosteroids, the patient required ventilatory support and vasopressors on day 1. On day 2, tocilizumab was administered, resulting in a rapid and significant reduction in IL-6 levels. Subsequently, the patient\u2019s symptoms, including fever, dyspnea, and hypotension, resolved, and he was discharged on day 5. This case demonstrates that tocilizumab can be an effective intervention in managing severe HSRs associated with CRRs. To our knowledge, this is the first reported instance of tocilizumab successfully salvaging a patient experiencing oxaliplatin-induced HSR. Nevertheless, further research is required to validate the efficacy of tocilizumab in treating oxaliplatin-induced HSRs.<\/jats:p>","DOI":"10.3389\/fphar.2024.1471038","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T09:52:53Z","timestamp":1736934773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Case report: Tocilizumab for hypersensitivity reaction after oxaliplatin in a patient with NK\/T-cell lymphoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Juanyan","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s12016-022-08932-2","article-title":"Premedication protocols to prevent hypersensitivity reactions to chemotherapy: a literature review","volume":"62","author":"Almuhizi","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","article-title":"Clinical features and severity grading of anaphylaxis","volume":"114","author":"Brown","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3892\/etm.2020.9456","article-title":"Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review)","volume":"21","author":"Chen","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00296-009-0885-8","article-title":"IL-6\/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system","volume":"29","author":"Hashizume","year":"2009","journal-title":"Rheumatol. Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ni.3632","article-title":"Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells","volume":"18","author":"Heink","year":"2017","journal-title":"Nat. Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/all.15940","article-title":"Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: phenotypes, endotypes, and management with desensitization","volume":"79","author":"Jimenez-Rodriguez","year":"2024","journal-title":"Allergy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1042\/CS20110340","article-title":"IL-6\/IL-6 receptor system and its role in physiological and pathological conditions","volume":"122","author":"Mihara","year":"2012","journal-title":"Clin. Sci. (Lond)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/jjco\/hyv081","article-title":"Platinum hypersensitivity and desensitization","volume":"45","author":"Miyamoto","year":"2015","journal-title":"Jpn. J. Clin. Oncol."},{"key":"B12","volume-title":"Common Terminology criteria for adverse events (CTCAE) v5.0","year":"2017"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1093\/rheumatology\/kead416","article-title":"Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus","volume":"62","author":"Nepal","year":"2023","journal-title":"Rheumatol. Oxf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/all.15113","article-title":"Hypersensitivity reactions to chemotherapy: an EAACI position paper","volume":"77","author":"Pagani","year":"2022","journal-title":"Allergy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.3390\/ijms22063059","article-title":"Therapeutic role of tocilizumab in SARS-CoV-2-induced cytokine storm: rationale and current evidence","volume":"22","author":"Pelaia","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.3324\/haematol.2023.284564","article-title":"Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"109","author":"Perl","year":"2024","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/s1074-7613(00)80334-9","article-title":"Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment","volume":"6","author":"Romano","year":"1997","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","article-title":"Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience","volume":"13","author":"Scott","year":"2023","journal-title":"Blood Cancer J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.jaip.2020.02.013","article-title":"Endophenotyping oxaliplatin hypersensitivity: personalizing desensitization to the atypical platin","volume":"8","author":"Silver","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/postgradmedj-2014-132686","article-title":"Evaluation and management of hypersensitivity reactions to chemotherapy agents","volume":"91","author":"Tham","year":"2015","journal-title":"Postgrad. Med. J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.3390\/jcm10215190","article-title":"Cytokine release syndrome in the immunotherapy of hematological malignancies: the biology behind and possible clinical consequences","volume":"10","author":"Tvedt","year":"2021","journal-title":"J. Clin. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1471038\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T09:52:59Z","timestamp":1736934779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1471038\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":21,"alternative-id":["10.3389\/fphar.2024.1471038"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1471038","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"article-number":"1471038"}}